SPOTLIGHT: Corautus restructures


The CEO and CFO of Corautus Genetics are resigning after the failure of its VEGF-2 therapy in a recent trial. The company says that it is abandoning the therapy and reducing staff as it restructures and hunts for an acquisition or licensing deal. Several other top executives, including the CSO, are being terminated before the end of the year. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.